Iterative Health

AI-driven solutions for gastrointestinal care

Boston, Massachusetts, United States

About Iterative Health

Iterative Health focuses on improving gastrointestinal (GI) care through the use of artificial intelligence (AI) and machine learning (ML). Their main product, SKOUT®, is an FDA-cleared device designed to help doctors detect adenomas, which are precursors to colorectal cancer. This device works alongside physician judgment to enhance the accuracy of diagnoses. In addition to SKOUT®, Iterative Health provides services that optimize clinical trials by using AI-enabled documentation technology, which improves patient care and ensures high-quality reporting across different healthcare institutions. This technology aims to make advanced care more accessible, especially to underserved populations. Unlike many competitors, Iterative Health combines AI technology with a strong focus on colorectal cancer prevention and clinical trial efficiency. The company's goal is to deliver top-tier GI care and improve health outcomes for patients worldwide.

Boston, MassachusettsHeadquarters
2017Year Founded
$182.1MTotal Funding
SERIES_BCompany Stage
AI & Machine Learning, HealthcareIndustries
51-200Employees

Benefits

Vision/Dental/ Medical Insurance
Life/Disability Insurance
Parental Leave
Stock Options
Flexible Work Hours
Unlimited Paid Time Off

Risks

Competition from tech giants in AI medical imaging threatens Iterative Health's market share.
Rapid expansion and partnerships may strain operational capabilities and resources.
Reliance on AI exposes Iterative Health to potential ethical and regulatory scrutiny.

Differentiation

Iterative Health uses AI to enhance GI care, focusing on colorectal cancer prevention.
Their SKOUT® device aids in adenoma detection, improving diagnostic accuracy in endoscopy.
AI-enabled documentation technology optimizes clinical trials, enhancing research quality and continuity.

Upsides

AI-driven predictive analytics in gastroenterology allow for personalized, effective patient care.
Partnerships with Gastro Health and One GI® expand clinical research capabilities in GI care.
$150M Series B funding accelerates AI innovations, transforming gastroenterology care.